期刊文献+

表观扩散系数预测直肠癌术前放化疗疗效分析 被引量:7

Predictive value of apparent diffusion coefficient for efficacy of preoperative chemoradiotherapy for locally advanced rectal cancer
原文传递
导出
摘要 目的 探讨表观扩散系数(ADC)预测局部晚期直肠癌术前放化疗疗效的作用.方法 2007-2011年间前瞻性纳入病理证实的临床Ⅱ、Ⅲ期直肠腺癌患者70例.均行术前同期放化疗,盆腔放疗44.0 ~50.4 Gy分22 ~ 28次,同期化疗卡培他滨每天1 650 mg/m2第1 ~ 35天+奥沙利铂50mg/m2每周1次共5次,放化疗后4~8周行根治性手术.疗前常规行盆腔MRI及扩散加权成像检查,测量ADC值并行术后病理反应评级.Mann-Whitney U检验法分析组间ADC值差异,Kaplan-Meier法计算生存率并Logrank法检验.结果 70例患者中7例(10%) pCR、38例(54%)降期.中位随访34个月,22例(31%)复发.疗前、疗中、疗后平均ADC值分别为(1.09±0.19) ×10-3、(1.28±0.19)×10-3、(1.47 ±0.24)×10-3 mm2/s.预后较好组(pCR、降期、无复发)疗前平均ADC值低于预后不良组(P =0.049、0.001、0.029).取疗前ADC值1.06×10-3 mm2/s为界值预测降期,ROC曲线下面积为0.737(95%CI=0.618 ~0.856).疗前ADC值<1.06 ×10-3 mm2/s组3年DFS和DMFS均高于≥1.06×10-3 mm2/s组,分别为86%比58% (P =0.01)和90%比60% (P =0.01).结论 疗前ADC值与局部晚期直肠癌术前同期放化疗疗效有一定相关性,对预测直肠癌术前放化疗疗效有一定意义. Objective To investigate the value of apparent diffusion coefficient (ADC) in predicting the efficacy of preoperative chemoradiotherapy (PCRT) for locally advanced rectal cancer.Methods From 2007 to 2011,70 patients with histopathologically proven clinical stage Ⅱ / Ⅲ rectal cancer were enrolled prospectively.All patients received PCRT,with radiotherapy (44.0-50.4 Gy/22-28 fractions) delivered to the pelvis and concurrent chemotherapy with capecitabine (l 650 mg/m2 per day,d 1-35) and oxaliplatin (50 mg/m2,once weekly,5 times),and radical surgery performed at 4-8 weeks after PCRT.Diffusion-weighted MRI was performed in all patients before PCRT,and ADC values were calculated.The pathologic tumor regression grade was assessed after surgery.The difference in ADC between groups was analyzed by nonparametric Mann-Whitney U test.Survivals were analyzed by the Kaplan-Meier method and compared by the log-rank test.Results Among 70 patients,7 (10%) achieved a pathological complete response (pCR),and 38 (54%) were downstaged.With a median follow-up of 34 months,22 (31%) patients experienced recurrence.The mean ADC values before,during,and after PCRT (pre-ADC,during-ADC,and post-ADC) were (1.09 ± 0.19) × 10-3 mm2/s,(1.28 ± 0.19) × 10-3 mm2/s,and (1.47 ± 0.24) × 10-3 mm2/s,respectively.The mean pre-ADCs for favorable groups (pCR,downstaging,and no recurrence) were significantly lower than those for unfavorable groups (P=0.049,0.001,and 0.029).When a pre-ADC value of 1.06 × 10-3 mm2 / s was used as the cut-off value for predicting downstaging,the area under the receiver operating characteristic curve was 0.737 (95%CI =0.618-0.856).The 3-year disease-free survival and distant metastasis-free survival for patients with pre-ADCs of 〈 1.06 × 10-3 mm2/s were 86% and 90%,respectively,which were significantly higher than those for patients with pre-ADCs of ≥ 1.06 × 10-3 mm2/s (58% and 60%) (P =0.010 for both).Conclusions Pre-ADC correlates to the efficacy of PCRT for locally advanced rectal cancer,so it has good prognostic value for this disease after PCRT.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2014年第3期194-198,共5页 Chinese Journal of Radiation Oncology
基金 北京科委重大课题(No.D0905001040531)
关键词 磁共振成像 扩散加权 直肠肿瘤 放化疗法 直肠肿瘤 外科学 预后 Magnetic resonance imaging, diffusion-weighted Rectal neoplasms/radiochemotherapy Rectal neoplasms/surgery Prognosis
  • 相关文献

参考文献32

  • 1Saner R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer [J]. N Engl J Med ,2004,351 : 1731-1740.
  • 2Sebag-Montefiore D, Stephens R J, Steele R, et at. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016) :a multicentre, randomised trial [J]. Lancet,2009,373:811:820.
  • 3Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer:preliminary resuhs-EORTC 22921 [J]. J Clin Oncol, 2005,23:5620-5627.
  • 4Gerard JP, Conrey T, Bonnetain F, et at. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers:results of FFCD 9203 [J]. J Clin Oncol, 2006,24:4620-4625.
  • 5Roh MS, Colangelo LH, O' Connell MJ, et at. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 [J]. J Clin Oncol, 2009,27:5124-5130.
  • 6Park JH, Yoon SM, Yu CS, et at. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer [ J]. Cancer, 2011 , 117:3703-3712.
  • 7Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase IH trial ACCORD 12/0405- Prodige 2 [ J]. J Clin Oneo1,2010,28 : 1638-1644.
  • 8Rodel C, Liersch T, Becker H, et at. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouraeil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ A10-04 randomised phase 3 trial [J]. Lancet Onc01,2012, 13: 679-687.
  • 9Aschele C, Cionini L, Lonardi S, et at. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase !II trial [J]. J Clin Oncol, 2011 , 29: 2773- 2780.
  • 10Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer:long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01 ) [J]. Ann Surg ,2010,252:998-1004.

二级参考文献13

  • 1孙应实,张晓鹏,唐磊.直肠癌扩散加权成像b值选取及其对直肠癌显示能力的评价[J].中国医学影像技术,2005,21(12):1839-1843. 被引量:44
  • 2Kapiteijn E,Marijnen CA,Nagtegaal ID,et al.Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.N Engl J Med,2001,345:638-646.
  • 3Maiding AL,Holm T,Rutqvist LE,et al.Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm.Stockholm Colorectal Cancer Study Croup,Basingstoke Bowel Cancer Research Project Lancet,2000,356:93-96.
  • 4Folkesson J,Birgisson H,Pahlman L,et al.Swedish Rectal Cancer Trial:long lasting benefits from radiotherapy on survival and local recurrence rate.J Clin Oncol,2005,23:5644-5650.
  • 5Ortholan C,Francois E,Thomas O,et al.Role of radiotherapy with surgery for t3 and resectable t4 rectal cancer;evidence from randomized trials.Dis Colon Rectum,2006,49:302-310.
  • 6Allen SD,Padhani AR,Dzik-Jurasz AS,et al.Rectal carcinoma:MRI with histologic correlation before and after chemoradiation therapy.AJR,2007,188:442-451.
  • 7Dzik-Jurasz A,Domenig C,George M,et al.Diffusion MRI for prediction of response of rectal cancer to chemoradiation.Lancet,2002,360:307-308.
  • 8Kremser C,Judmaier W,Hein P,et al.Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging.Strahlenther Onkol,2003,179:641-649.
  • 9Greene FL,Page DL,Fleming ID,et al.AJCC cancer staging handbook.6 th ed New York:NY Springer Verlag,2002:113-123.
  • 10Berger C,de Muret A,Garaud P,et al.Preoperative radiotherapy(RT)for rectal cancer;predictive factors of tumor downstaging and residual tumor cell density(RTCD):prognostic implications.Int J Radiat Oncol Biol Phys,1997,37:619-627.

共引文献22

同被引文献88

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部